Persistence of monoclonal B‐cell expansion and intraclonal diversification despite virus eradication in patients affected by hepatitis C virus‐associated lymphoproliferative disorders
British Journal of Haematology · 2023-10 · 203 (2) · 237-243
DOI: 10.1111/bjh.19002 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 25.07.2023. Verfasst von Cesare Mazzaro und 13 weiteren Autor:innen. Beteiligte Einrichtung: Clinical and Experimental Onco-Haematology Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy. Hauptthemen laut MEDLINE: Lymphoproliferative Disorders, B-Lymphocytes, Hepacivirus, Hepatitis C. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Associazione Italiana per la Ricerca sul Cancro, Ministero della Salute, Fondazione Giulia Maramotti e Fondazione GRADE Onlus.
Abstract (Originalsprache)
We investigated 23 hepatitis C virus (HCV)‐infected patients with overt lymphoproliferative diseases (15 cases) or monoclonal B lymphocytosis (8 cases) treated with direct agent antiviral (DAAs) per clinical practice. DAA therapy yielded undetectable HCV‐RNA, the complete response of cryoglobulinemia vasculitis and related signs, whilst the presence of B‐cell clones (evaluated by flow cytometry, IGHV, and BCL2‐IGH rearrangements), detected in 19/23 cases at baseline, was maintained (17/19). Similarly, IGHV intraclonal diversification, supporting an antigen‐driven selection mechanism, was identified in B‐cell clones at baseline and end of follow‐up. DAA therapy alone, despite HCV eradication and good immunological responses, was less effective on the pathological B‐cell clones.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical and Experimental Onco-Haematology Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy.
- Division of Clinical Immunology, Department of Internal Medicine, Sapienza Unversity of Rome, Rome, Italy.
- Department of Translational Research and New Technologies in Medicine and Surgery, Medical School, University of Pisa, Pisa, Italy.
- Centro Manifestazioni Sistemiche da Virus Epatitici, University of Florence, Florence, Italy.
ORCID-Profile: Marcella Visentini, Riccardo Bomben
Förderung
- Associazione Italiana per la Ricerca sul Cancro
- Ministero della Salute
- Fondazione Giulia Maramotti e Fondazione GRADE Onlus
- Associazione Italiana contro le Leucemie, linfomi e mielomi (AIL)
- Centro di Riferimento Oncologico
Zitieren
APA
Mazzaro, C., Visentini, M., Gragnani, L., Vit, F., Tissino, E., Pozzo, F., Papotti, R., Casato, M., Zignego, A. L., Bittolo, T., Zucchetto, A., Degan, M., Bomben, R., & Gattei, V. (2023). Persistence of monoclonal B‐cell expansion and intraclonal diversification despite virus eradication in patients affected by hepatitis C virus‐associated lymphoproliferative disorders. British Journal of Haematology, 203(2), 237-243. https://doi.org/10.1111/bjh.19002
Vancouver
Mazzaro C, Visentini M, Gragnani L, Vit F, Tissino E, Pozzo F, et al. Persistence of monoclonal B‐cell expansion and intraclonal diversification despite virus eradication in patients affected by hepatitis C virus‐associated lymphoproliferative disorders. British Journal of Haematology. 2023;203(2):237-243. doi:10.1111/bjh.19002
BibTeX
@article{Mazzaro2023,
author = {Mazzaro, Cesare and Visentini, Marcella and Gragnani, Laura and Vit, Filippo and Tissino, Erika and Pozzo, Federico and Papotti, Robel and Casato, Milvia and Zignego, Anna Linda and Bittolo, Tamara and Zucchetto, Antonella and Degan, Massimo and Bomben, Riccardo and Gattei, Valter},
title = {Persistence of monoclonal B‐cell expansion and intraclonal diversification despite virus eradication in patients affected by hepatitis C virus‐associated lymphoproliferative disorders},
journal = {British Journal of Haematology},
year = {2023},
volume = {203},
number = {2},
pages = {237--243},
doi = {10.1111/bjh.19002}
}
EUVIMED